Tonix Pharmaceuticals (NASDAQ:TNXP) Director Acquires $58,250.00 in Stock

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Director Richard Newcomb Stillwell acquired 5,000 shares of the stock in a transaction dated Monday, June 8th. The stock was acquired at an average cost of $11.65 per share, with a total value of $58,250.00. Following the transaction, the director directly owned 5,000 shares in the company, valued at approximately $58,250. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Tonix Pharmaceuticals Stock Down 2.1%

Shares of Tonix Pharmaceuticals stock traded down $0.25 during trading on Tuesday, reaching $11.46. The company’s stock had a trading volume of 544,959 shares, compared to its average volume of 425,927. The company has a 50-day simple moving average of $13.20 and a two-hundred day simple moving average of $15.06. Tonix Pharmaceuticals Holding Corp. has a 1-year low of $10.87 and a 1-year high of $69.97. The company has a market cap of $182.68 million, a price-to-earnings ratio of -0.80 and a beta of 1.67.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings results on Monday, May 11th. The company reported ($2.93) EPS for the quarter, missing analysts’ consensus estimates of ($2.54) by ($0.39). Tonix Pharmaceuticals had a negative return on equity of 67.65% and a negative net margin of 839.52%.The firm had revenue of $6.88 million for the quarter, compared to analyst estimates of $6.13 million. As a group, analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -9.94 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on TNXP. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research report on Monday, April 20th. TD Cowen raised Tonix Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, May 5th. Finally, Wall Street Zen cut Tonix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, April 26th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.00.

Hedge Funds Weigh In On Tonix Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Bank of America Corp DE lifted its holdings in shares of Tonix Pharmaceuticals by 101.1% in the 1st quarter. Bank of America Corp DE now owns 60,958 shares of the company’s stock valued at $838,000 after buying an additional 30,644 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Tonix Pharmaceuticals by 26.4% in the 1st quarter. Bank of New York Mellon Corp now owns 30,426 shares of the company’s stock valued at $418,000 after buying an additional 6,362 shares during the period. SJS Investment Consulting Inc. acquired a new position in shares of Tonix Pharmaceuticals in the 1st quarter valued at about $138,000. Man Group plc acquired a new position in shares of Tonix Pharmaceuticals in the 4th quarter valued at about $288,000. Finally, Engineers Gate Manager LP lifted its holdings in shares of Tonix Pharmaceuticals by 63.7% in the 4th quarter. Engineers Gate Manager LP now owns 14,263 shares of the company’s stock valued at $223,000 after buying an additional 5,550 shares during the period. Institutional investors and hedge funds own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.